SLC1A5 and head and neck squamous cell carcinoma: Previous studies found that ASCT2 forms a heterotrimeric molecular complex with EGFR and AP1G1; thus, cetuximab could co-target ASCT2 via EGFR endocytosis and decrease intracellular glutamine levels in HNSCC.20,22 In contrast, the effect of ASCT2 targeting on the response of HNSCC to cetuximab remained unclear.